Biodesix (BDSX) Q4 2025 earnings review
Biodesix Crosses the Profitability Rubicon on Surging Primary Care Volume
Biodesix delivered a milestone quarter, achieving its first-ever positive Adjusted EBITDA ($0.5M) while accelerating revenue growth to 41% YoY. The controversial early-year decision to restructure the sales force and target primary care networks has definitively paid off, driving a 23% spike in diagnostic test volumes and pushing gross margins to a record 83%. While cash burn remains a lingering reality—evidenced by a post-quarter $14.7M capital raise—the operational leverage is now clearly visible. FY26 guidance calls for a stable 23% growth rate, suggesting the new sales structure has sustainable momentum.
🐂 Bull Case
Gross margins hit 83% and operating expenses grew at just one-third the pace of revenue (14% vs 41%). The diagnostic testing model is proving it can scale profitably without runaway SG&A costs.
Test volumes accelerated 23% YoY to 18,000 in Q4. The pivot to targeting upstream primary care physicians has dramatically expanded the addressable market beyond traditional pulmonologists.
🐻 Bear Case
Q4 diagnostic revenue included $1.0 million in collections from claims older than a year. Without this, organic growth was slightly lower at 40%, meaning structural Average Selling Price (ASP) improvements might be overstated.
Despite hitting positive EBITDA, the company still consumed cash, leaning on its ATM facility for $2.3M in Q4 and raising another $14.7M post-quarter. GAAP profitability remains elusive.
⚖️ Verdict: 🟢
Bullish. Management executed exactly what they promised after the Q1 stumble: they re-accelerated volume growth through the primary care channel, maintained severe cost discipline, and delivered positive EBITDA. The business model is demonstrating significant structural leverage.
Key Themes
Primary Care Expansion Accelerating Volume
After a rocky Q1 where sales rep reconfiguration caused a guidance cut, the pivot to primary care networks is clearly working. Diagnostic Test revenue accelerated 46% YoY in Q4 to $25.1M, driven by a 23% increase in test volumes (18,000 tests). The strategy of targeting the ~15,000 PCPs who manage 80% of upstream lung nodule patients is driving strong volume growth and effectively expanding the total addressable market.
Gross Margin Reversing Cash Burn Trends
A hallmark of Q4 was the rapid expansion of margins. Gross margin expanded 400bps YoY to 83%, up significantly from 79.4% in Q1. Operating expenses grew only 14% against 41% revenue growth, proving the inherent operating leverage in the diagnostic testing model as the expanded sales team moves up the productivity curve. This structural leverage allowed Adjusted EBITDA to reverse from a $6.2M loss in Q1 to a positive $0.5M in Q4.
Reliance on Old Claim Collections for ASP Bump
While Q4 diagnostic revenue accelerated sharply (+46% YoY), it was partially inflated by approximately $1.0 million in collections from claims older than one year. Core organic revenue for diagnostic tests, excluding these old claims, was $24.1 million (+40% YoY). While still an accelerating trend, investors must strip out this specific one-time collection windfall to accurately assess structural Average Selling Price (ASP) improvements.
Ongoing Share Dilution Despite Profitability Milestone
Even with Q4's positive Adjusted EBITDA, cash consumption remains a factor. The company utilized $2.3 million from its At-The-Market (ATM) facility in Q4, and subsequently raised another $14.7 million after the quarter ended. They also amended their Perceptive Advisors term loan to extend the interest-only period to 2028. While this secures the balance sheet, it highlights that GAAP profitability and positive free cash flow are still quarters away, subjecting shareholders to continued dilution.
Payer Coverage Concentration Risk
The company noted in prior quarters that improvements in ASP were heavily reliant on resolving payment delays with a single large Medicare Advantage plan and securing additional payer coverage. Any future disruptions or macro policy changes from major Medicare networks could quickly reverse recent ASP gains and compress gross margins.
Multi-Omic Platform and Digital Enhancements
Biodesix is enhancing its operational moat through technologies like digital ordering via Redox EMR integrations and on-site blood draws using the Tasso device, which previously demonstrated a 30% increase in test completion rates. Simultaneously, the company is advancing a new combination genomic and proteomic Minimal Residual Disease (MRD) test for biopharma partners, highlighting continuous product innovation.
Other KPIs
Accelerating. Up 41% YoY from $6.6 million in FY24. Q4 alone delivered $3.6 million (+12% YoY). This segment benefits from a growing book of contracted business with biopharma partners and acts as a high-margin diversifier to the core clinical testing volume.
Up significantly from $19.0 million at the end of Q4. The pro forma number includes $14.7 million raised subsequent to quarter-end. This is a substantial improvement in liquidity compared to Q3 ($16.6M), giving the company sufficient runway to transition its positive Adjusted EBITDA into sustained cash flow breakeven.
Reversing trajectory. An impressive 52% improvement YoY from -$8.3M in 24Q4. The path to GAAP profitability is accelerating rapidly, driven by the 83% gross margin and contained operating expense growth.
Guidance
Stable. The midpoint of $109 million implies 23% YoY growth, matching the strong 24% growth rate achieved in FY25. Management attributes this forward trajectory to increasing productivity across the newly expanded sales organization and structural improvements to average revenue per test.
Stable. Management expects to maintain gross margins around 80%, slightly below the 83% peak achieved in 25Q4 but consistent with the 81% average for the full FY25 year.
Key Questions
Structural ASP vs One-Time Collections
The $1.0 million collection from old claims aided Q4 ASP and revenue growth. What is the normalized ASP heading into Q1 2026, and how much remaining older claims inventory is left to collect?
Timeline to Free Cash Flow Breakeven
With Adjusted EBITDA now positive, what is the realistic timeline to achieving sustained Free Cash Flow breakeven, and does the recent $14.7M post-quarter raise fulfill all capital needs until that crossover point is reached?
Sales Force Productivity Limits
The sales force reached its target headcount late in 2025. What is the expected steady-state revenue productivity per rep in 2026, and will you need to add more territories to achieve the upper end of your $112 million guidance?